# Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

> **NCT02267967** · PHASE1 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 81 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Sulfatinib

## Key facts

- **NCT ID:** NCT02267967
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-31
- **Primary completion:** 2017-08-23
- **Final completion:** 2017-08-23
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2018-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267967, "Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02267967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*